Buckle Up for Breast Cancer—Deaths from Breast Cancer Can Be Analyzed in the Same Way as Deaths in Automobile Accidents

Matthew L Webb, AB,1 Blake Cady, MD2 and James S Michaelson, PhD3

1. Research Assistant, Department of Surgical Oncology, and Research Coordinator, Endocrine Unit, Massachusetts General Hospital; 2. Emeritus Professor of Surgery, Brown Medical School, and Director, Breast Health Center, Woman and Infants Hospital of Rhode Island; 3. Assistant Professor of Pathology, Departments of Pathology and Surgery, Massachusetts General Hospital, and Department of Pathology, Harvard Medical School

Abstract

Background: Randomized population mammographic screening trials demonstrated a statistically significant mortality reduction in screened women. Studies in Sweden and The Netherlands show that screening is the main reason that the death rate has decreased in the general population, but only limited data are available to assess this in the US. In a previous report, 75% of breast cancer deaths occurred in the small proportion of unscreened women. This conclusion needs confirmation. Methods: In a large hospital consortium, 6,997 invasive breast cancer diagnoses occurred between 1990 and 1999. Among all subsequent deaths through 2007, breast cancer deaths in Massachusetts women were documented by review of hospital and outpatient records. Regular screening was defined as two or more screening mammograms at intervals of two years or less in asymptomatic women. Results: After 12.5 (range: eight to 17) years of median follow-up, 461 deaths from breast cancer were confirmed. Seventy-two deaths (15.6%) resulted from non-palpable screen-detected cancers, 44 deaths (9.6%) resulted from palpable interval cancers, and a total of 116 deaths (25.2%) occurred in regularly screened women. Three hundred and twenty-two deaths (69.9%) occurred in women who had never had screening mammography, and 23 deaths (5%) occurred after one or more previous mammograms, none within two years of diagnosis. Thus, 345 breast cancer deaths (74.8%) occurred in women who were not regularly screened. Conclusion: The most effective method of avoiding death from breast cancer is for women to participate in regular screening mammography.

Keywords

Mammography, screening mammography, breast cancer, breast cancer mortality

Disclosure: The authors have no conflicts of interest to declare.

Received: March 18, 2010 Accepted: October 4, 2010 Citation: US Oncological Review, 2010;6:36–8 DOI: 10.17925/OHR.2010.06.0.36

Correspondence: Blake Cady, MD, 24 Walnut Place, Brookline, MA 02445. E: bcady123@comcast.net

In the US, breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. There were expected to be 192,370 new diagnoses of invasive breast cancer in the US in 2009, and of that number we estimate that 28,856 (15%) will die of the disease by 2022, considering that the overall mortality rate is steadily decreasing by about 2% per year.1

Early diagnosis and treatment can dramatically increase the likelihood that a woman diagnosed with breast cancer in 2009 will not be among the 15% who will die, because screening mammography has the dramatic impact of facilitating earlier diagnosis. A recent review of the eight major prospective randomized population-based trials of mammography screening concluded that the policy of offering screening is associated with a significant and substantial reduction in breast cancer mortality, whether or not those offered screening were actually screened,2 commonly observed to be between 25 and 45% in women over 50 years of age and between 15 and 25% in women of all ages.1 This mortality reduction occurs despite the compliance and contamination biases that result from women offered screening (experimental group) but who did not actually receive mammography (non-compliant), and women not offered screening (control group) who nevertheless actually had screening mammography (contamination). One study of women actually receiving regular population screening mammography demonstrated an even greater mortality reduction of over 50%.2

Such clear science in favor of the benefits of screening mammography should leave little doubt about its effectiveness, but a recent report from the US Preventive Services Task Force (USPSTF) has added controversy as to the frequency, effectiveness, and costs of screening mammography.3 We performed a study that looked not to the future, as in screening mammography prospective trials, but to past experience with screening and asked, retrospectively, ‘Of women who died of breast cancer, what was their experience with screening mammography?’ Our hypothesis was that among women who die of breast cancer, the majority did not participate in screening mammography. We examined complete medical records of women who actually died from their breast cancer to determine whether or not they had participated in regular mammographic screening. Ours was a similar exercise to that which proved the efficacy of safety belts
Deaths from Breast Cancer Can Be Analyzed in the Same Way as Deaths in Automobile Accidents

in automobiles: look back at fatal car accidents and determine whether or not those killed had been wearing their seat belts.

In 1984 the US National Highway Traffic Safety Administration estimated that safety belts reduced the fatality risk of front-seat occupants of passenger cars by 45% relative to unrestrained occupants. A more recent 2009 analysis compared fatality data from belt use observed in local and national surveys of automobile accidents. This analysis reconfirmed the agency’s earlier estimates of a fatality reduction of 45% in passenger car accidents by use of seat belts. Furthermore, the analysis allowed additional inquiries, permitting estimation of belt effectiveness by crash type, occupant age, gender, belt type, vehicle type, and other criteria.6

Methods

In a similar fashion, we analyzed breast cancer deaths among women treated in a large hospital consortium by comparing the history of mammography in women who died from breast cancer and the rate of screening reported by a national, biannual, standardized telephone survey: the Behavioral Risk Factor Surveillance Survey (BRFSS). Our results show that 75% of breast cancer deaths among the patients we studied occurred in the 20% of women not in regular screening programs. Furthermore, our analysis of fatal breast cancers permitted additional inquiries that revealed demographic relationships such as age at diagnosis, duration of survival, pathologic characteristics such as tumor size, grade, and nodal status, and interval between mammography screenings.

Of course, not every driver will be involved in a motor vehicle accident. In fact, most drivers will never be in an accident, just as most women will never develop breast cancer. Of people who are in accidents, however, those who are wearing their seat belts are much more likely to survive. Likewise, while most women will never develop breast cancer, of those who do develop cancers, those whose cancers are found on a routine screening mammogram are much less likely to die from the disease.

Using longitudinal electronic medical records, we identified nearly 7,000 women in a large hospital consortium in Boston, MA who were diagnosed with invasive breast cancer between 1990 and 1999. Of the 873 women who died from any cause over a median follow-up of 12.5 years (range eight to 17 years), we confirmed that roughly half had died from their breast cancer, and of those women who died, 75% either had never received screening mammography or had not received a screening mammogram in the two years prior to diagnosis.

Results

The mechanism by which a seat belt prevents death during a car accident is fairly clear: it prevents secondary collisions with the steering wheel, dashboard, windshield, or other internal objects after the abrupt stoppage of the primary collision. Likewise, the reason screening mammography prevents death from breast cancer is just as clear: it identifies cancers when they are so small that they have not secondarily spread to other parts of the body to form clinical metastases. Randomized trials of screening mammography reveal that screened women present with invasive breast cancers of significantly smaller sizes and consequently display considerable reductions in risk of death. Trials using poor-quality mammography in which the size of invasive breast cancers was not remarkably different between experimental or screened women and control or unscreened women—such as the Canadian National Breast Screening Studies—do not display a reduction in breast cancer mortality.2 Screening mammography thus decreases breast cancer mortality by discovering smaller cancers with fewer lymph-node metastases and of lower grade, for which treatments are much more effective.3

The largest proportion of the reduction in breast cancer deaths since widespread screening began in the 1980s is attributable to this reduction of tumor size by early detection.7 In Holland, screening mammography was introduced in different municipalities at different times as equipment was obtained and radiologists were trained. When the date of mammography introduction in these various municipalities throughout the country was designated as the common point of onset of screening, it was noted that 80% of the reduction in mortality was due to screening and only 20% to systemic therapy.8

Implementation of the Norwegian Breast Cancer Screening Program demonstrated that organized, population-based screening increases the frequency of the favorable prognostic characteristics of smaller size, fewer nodal metastases, and more breast conservation rather than mastectomy.9 For example, in a prospective breast cancer screening program introduced in Northeast Spain, node involvement was significantly reduced in cancers detected by screening relative to those detected by any other method.10

Our retrospective study supports the findings of these prospective reports and trials as the screen-detected tumors we found—even though they were fatal—were much smaller with lower grade and fewer nodal metastases than those detected only by palpating a mass. Screening mammography decreases mortality by discovering breast cancers with much more favorable prognostic characteristics that are more successfully treated than cancers discovered at a later stage with larger, palpable masses, similar to all breast cancers discovered before the introduction of screening mammography.

It is important to note that virtually all patients who die of breast cancer receive systemic chemical or hormone therapy at some point in their disease course, emphasizing the imperative of earlier detection, despite the use of systemic adjuvant treatments. Also, just as seat belt use does not prevent all deaths in automobile accidents but rather drastically reduces the risk of death, so screening mammography does not eliminate all deaths from breast cancer but markedly reduces them.

Discussion

BRFSS telephone surveys are conducted every two years in all states; almost 80% of Massachusetts women in 1995 reported having received a mammogram in the previous two years, and this mid-point in time of our patient population was selected as the average screening rate between 1990 and 1999.11 We demonstrated that 75% of deaths from breast cancer in our patients occurred in the 20% of women not participating in regular screening mammography, while only 25% of deaths occur in the 80% of regularly screened women. These results are similar to a previous retrospective study of deaths from breast cancer in Rhode Island that demonstrated that 72% of breast cancer deaths occurred in the 15% of women not regularly screened.12 These two
Breast Cancer

The findings of our retrospective research are consistent with the large body of prior prospective randomized trials on the efficacy of screening mammography. The most compelling aspect of our current research is its simple reproducibility in further studies, which may be undertaken wherever accurate and complete medical records exist. While our retrospective study would not be accepted as ‘evidence-based,’ as prospective randomized trials would be, such retrospective reports contribute to the recognition of what is really a remarkable public health achievement: the substantial and convincing marked reduction of deaths from women’s most feared cancer. Achievement of the American Cancer Society’s goal of a 50% reduction in breast cancer mortality by 2015 is clearly possible, and may be exceeded in many states with widespread population screening mammography.

Matthew J. Webb, AB, is a Research Assistant in the Department of Surgical Oncology and a Research Coordinator in the Endocrine Unit at Massachusetts General Hospital. He graduated from Harvard College in June 2009 and has since been involved in many studies of breast cancer. He is currently working on his medical degree at Harvard Medical School.

Blake Cady, MD, is Emeritus Professor of Surgery at Brown Medical School and Director of the Breast Health Center at Women and Infants Hospital of Rhode Island. Professor Cady has been President of several scientific organizations, including the Massachusetts Division of the American Cancer Society (ACS). He has also served on the national board of the ACS and has received the annual Distinguished Service Award of the ACS among other highly recognized awards. Professor Cady was founding Editor (now emeritus) of Surgical Oncology Clinics of North America and is the author of over 400 articles, book chapters, commentaries, and editorials in the surgical and oncologic literature. He lectures widely on numerous topics in surgical oncology.

James S Michaelson, PhD, is an Assistant Professor of Pathology in the Departments of Pathology and Surgery at the Massachusetts General Hospital, and the Departments of Pathology at Harvard Medical School. His research involves the collection of data and the development of improved mathematical methods for predicting cancer outcome, the analysis of cancer screening, and the use of modern computer speech and telephony to design systems that improve patient compliance. He received his doctorate in biology from Cornell University and post-doctoral training in immunogenetics from the Memorial Sloan-Kettering Institute.